Combined treatment modality for anaplastic oligodendroglioma and oligoastrocytoma: A 10-year update of a Phase II study

International Journal of Radiation Oncology Biology Physics

Volumn 59, Issue 2, 2004, Pages 509-514

  Jeremic, Branislav ^a,c   Milicic, Biljana ^a   Grujicic, Danica ^b   Samardzic, Miroslav ^b   Antunovic, Vaso ^b   Dagovic, Aleksandar ^a   Aleksandrovic, Jasna ^a  

^a University Hospital   (Serbia)

^b Clinical Center   (Serbia)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Anaplastic oligoastrocytoma; Anaplastic oligodendroglioma; Chemotherapy; Radiotherapy; Surgery

Indexed keywords

BIOPSY; CHEMOTHERAPY; RADIOTHERAPY; SURGERY; TOXICITY; TUMORS;

POSTOPERATIVE RADIOTHERAPY; TUMOR SIZE;

ONCOLOGY;

ANTINEOPLASTIC AGENT; LOMUSTINE; PROCARBAZINE; VINCRISTINE;

ADJUVANT CHEMOTHERAPY; ADULT; ALLERGIC REACTION; ALOPECIA; ARTICLE; ASTROCYTOMA; BLOOD TOXICITY; BRAIN DISEASE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DESQUAMATION; ERYTHEMA; EXTERNAL OTITIS; FATIGUE; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; LETHARGY; LEUKOPENIA; MALE; MUSCLE WEAKNESS; NAUSEA; OLIGODENDROGLIOMA; PARESTHESIA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; SEIZURE; SIDE EFFECT; SOMNOLENCE; THROMBOCYTOPENIA; TUMOR BIOPSY; VOMITING;

EID: 2442566831     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2003.10.020     Document Type: Article

References (54)

1. Chin H.W., Hazel J.J., Kim T.H., et al. Oligodendrogliomas A clinical study of cerebral oligodendrogliomas. Cancer. 45:1980;1458-1466
2. Mork S.J., Lindegaard K.K.F., Halvorsen T.B., et al. Oligodendroglioma Incidence and biological behavior in a defined population. J Neurosurg. 63:1985;881-889
3. Fortin D., Cairncross G.J., Hammond R.R. Oligodendroglioma An appraisal of recent data pertaining to diagnosis and treatment. Neurosurgery. 45:1999;1279-1291
4. Levin V.A., Edwards M.S., Wright D.C. Modified procarbazine, CCNU, and vincristine (PCV-3) combination chemotherapy in the treatment of malignant brain tumors. Cancer Treat Rep. 64:1980;237-241
5. Kristiansen K., Hagen S., Kollevold T., et al. Combined modality therapy of operated astrocytomas Grade III and IV - Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time A prospective multicenter trial of the Scandinavian Glioblastoma Study group. Cancer. 47:1981;649-652
6. Walker M.D., Alexander E., Hunt W.E., et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas A cooperative clinical trial. J Neurosurg. 49:1978;333-343
7. Walker M.D., Green S.B., Byar D.P., et al. Randomized comparison of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med. 303:1980;1323-1329
8. Jeremic B., Shibamoto Y., Grujicic D., et al. Combined treatment modality for anaplastic oligodendroglioma A phase II study. J Neurooncol. 43:1999;179-185
9. Allison R.R., Schulsinger A., Vongtama V., et al. Radiation and chemotherapy improve outcome in oligodendroglioma. Int J Radiat Oncol Biol Phys. 37:1997;399-403
10. Bullard D.E., Rawlings C.E., Phillips B., et al. Oligodendroglioma An analysis of the value of radiation therapy. Cancer. 60:1987;2179-2188
11. Gannett D.E., Wisbeck W.M., Silbergeld D.L., et al. The role of postoperative irradiation in the treatment of oligodendroglioma. Int J Radiat Oncol Biol Phys. 30:1994;567-573
12. Kim L., Hochberg F.H., Thornton A.F., et al. Procarbazine, lomustine, and vincristine (PCV) chemotherapy for grade III and IV oligoastrocytomas. J Neurosurg. 85:1996;602-607
13. Lindegaard K., Mork S.J., Eide G.E., et al. Statistical analysis of clinicopathological features, radiotherapy, and survival in 170 cases of oligodendroglioma. J Neurosurg. 67:1987;224-230
14. Shaw E.G., Scheithauer B.W., O'Fallon J.R., et al. Oligodendrogliomas The Mayo Clinic experience. J Neurosurg. 76:1992;428-434
15. Shaw E.G., Scheithauer B., O'Fallon J. Supratentorial gliomas A comparative study by grade and histologic type. J Neurooncol. 31:1997;273-278
16. Wallner K.E., Gonzales M., Sheline G.E. Treatment of oligodendrogliomas with or without post operative irradiation. J Neurosurg. 68:1988;684-688
17. Winger M.J., MacDonald D.R., Cairncross J.G. Supratentorial anaplastic gliomas in adults The prognostic importance of extent of resection and prior low-grade glioma. J Neurosurg. 71:1989;487-493
18. Zulch KJ. Histological typing of tumors of the central nervous system. World Health Organization (Intern Classification of Tumors), No. 21, 1979
19. Hart M.N., Petito C.K., Earle K.M. Mixed gliomas. Cancer. 33:1974;134-140
20. International Commission on Radiological Units and Measurements. ICRU Report Dose specification for reporting external beam therapy with photons and electrons. ICRU. 29:1978;3-13
21. Miller A.B., Hoogstraten B., Staquet M., et al. Reporting results of cancer treatment. Cancer. 47:1981;207-214
22. Cox J.D., Stetz J.A., Pajak T.F. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for the Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 31:1995;1341-1346
23. Cairncross J.G., MacDonald D.R. Chemotherapy for oligodendroglioma Progress report. Arch Neurol. 48:1991;225-227
24. Cairncross J.G., MacDonald D.R., Ramsay D.A. Aggressive oligodendroglioma A chemosensitive tumor. Neurosurgery. 31:1992;78-82
25. Cairncross J.G., MacDonald D., Ludwin S., et al. Chemotherapy for anaplastic oligodendroglioma. J Clin Oncol. 12:1994;2013-2021
26. Chinot O.-L., Honore S., Dufuor H., et al. Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. J Clin Oncol. 19:2001;2449-2455
27. Glass J.G., Hochberg F.H., Gruber M.L. The treatment of oligodendrogliomas and mixed oligodendrogliomas-astrocytomas with PCV chemotherapy. J Neurosurg. 76:1992;741-745
28. Kyritisis A.P., Yung W.K.A., Bruner J. The treatment of anaplastic oligodendrogliomas and mixed gliomas. Neurosurgery. 32:1993;365-371
29. MacDonald D.R., O'Brien R.A., Gilbert J.J., et al. Metastatic anaplastic oligodendroglioma. Neurology. 39:1989;1593-1596
30. MacDonald D.R., Gaspar L.E., Cairncross J.G. Successful chemotherapy for newly diagnosed aggressive oligodendroglioma. Ann Neurol. 27:1990;573-574
31. Paleologos N.A., MacDonald D.R., Vick N.A., et al. Neoadjuvant procarbazine, CCNU, and vincristine for anaplastic and aggressive oligodendroglioma. Neurology. 53:1999;1141-1143
32. Peterson K., Paleologos N., Forsyth P., et al. Salvage chemotherapy for oligodendroglioma. J Neurosurg. 85:1996;597-601
33. van den Bent M.J., Kros J.M., Heimans J.J., et al. Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Neurology. 51:1998;1140-1145
34. van den Bent M.J., Keime-Guibert F., Brandes A.A., et al. Temozolomide chemotherapy in recurrent oligodendroglioma. Neurology. 57:2001;340-342
35. Cairncross J.G., Ueki K., Zlatescu M.C., et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst. 90:1998;1473-1479
36. Smith J.S., Perry A., Borell T.J., et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol. 18:2000;636-645
37. Bauman G.S., Ino Y., Ueki K., et al. Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendroglioma. Int J Radiat Oncol Biol Phys. 43:2000;825-830
38. Ino Y., Betensky R.A., Zlatescu M.C., et al. Molecular subtypes of anaplastic oligodendroglioma Implications for patient management at diagnosis. Clin Cancer Res. 7:2001;839-845
39. Zlatescu M.C., TehraniYazdi A.R., Sasaki H., et al. Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms. Cancer Res. 61:2001;6713-6715
40. Reedy D.P., Bay J.W., Hahn J.F. Role of radiation therapy in the treatment of cerebral oligodendroglioma An analysis of 57 cases and a literature review. Neurosurgery. 13:1983;499-503
41. Cairncross J.G., MacDonald D.R. Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol. 23:1988;360-364
42. Krouwer H.G.J., van Duinen S.G., Kamphorst W., et al. Oligoastrocytomas A clinicopathological study of 52 cases. J Neurooncol. 33:1997;223-228
43. Bishop M., de la Monte S.M. Dual lineage of astrocytomas. Am J Pathol. 135:1989;517-527
44. de la Monte S.M. Uniform lineage of oligodendrogliomas. Am J Pathol. 135:1989;529-540
45. Allam A., Radwi A., El Weshi A. Oligodendroglioma An analysis of prognostic factors and treatment results. Am J Clin Oncol (CCT). 23:2000;170-175
46. Celli P., Nofrone I., Palma L., et al. Cerebral oligodendroglioma Prognostic factors and life history. Neurosurgery. 35:1994;1018-1034
47. Schiffer D., Dutto A., Cavalla P., et al. Prognostic factors in oligodendroglioma. Can J Neurol Sci. 24:1997;313-319
48. Shaw E.G., Scheithauer B.W., O'Fallon J.R., et al. Mixed oligoastrocytomas A survival and prognostic factor analysis. Neurosurgery. 34:1994;577-582
49. Sun Z.M., Genka S., Shitara N., et al. Factors influencing the prognosis of oligodendroglioma. Neurosurgery. 22:1988;886-891
50. Kros J.M., Pieterman H., van Eden C.G., et al. Oligodendroglioma The Roterdam-Dijkzigt experience. Neurosurgery. 34:1994;959-966
51. Kros J.M., van Eden C.G., Vissers C.J. Prognostic relevance of DNA flow cytometry in oligodendroglioma. Cancer. 69:1995;1791-1798
52. Nijjar T.S., Simpson W.J., Gadalla T., et al. Oligodendroglioma The Princess Margaret Hospital experience (1958-1984). Cancer. 71:1993;4002-4006
53. Peterson K., Cairncross J.G. Oligodendroglioma. Cancer Invest. 14:1996;243-251
54. Westergaard L., Gjeris F., Klinken L. Prognostic factors in oligodendrogliomas. Acta Neurochir (Wien). 139:1997;600-605